title: All that glitters: sorafenib.
authors.forename: Khurram
authors.initials: K
authors.lastname: Abbass
authors.forename: Shabana
authors.initials: S
authors.lastname: Dewani
authors.forename: Ronald
authors.initials: R
authors.lastname: Markert
authors.forename: Michael K
authors.initials: MK
authors.lastname: Kaplon
authors.forename: Michael A
authors.initials: MA
authors.lastname: Baumann
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D015275:Tumor Lysis Syndrome / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib